AIM - AIM ImmunoTech advances in Phase 1 study for COVID-19 therapy

Upon completion of the dosing of Cohort 1 in a Phase 1 trial evaluating the safety of Ampligen as an intranasal therapy, AIM ImmunoTech (AIM) is moving to the dose escalation of Cohort 2 after reporting no serious adverse events.The Phase 1 trial involving 40 healthy subjects is a ‘critical step’ in developing Ampligen as potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases, the company said.Noting that higher doses to be tested in Phase 1 may or may not be tolerable, AIM CEO Thomas K. Equels said, ‘we plan on moving quickly into Phase 2 studies with the doses that have successfully passed these Phase 1 tests, such as the dose used in Cohort 1.”In early March, AIM ImmunoTech announced the dosing initiation of the trial.

For further details see:

AIM ImmunoTech advances in Phase 1 study for COVID-19 therapy